Skip to main content

Recombinant Human Siglec-10 Fc Chimera Avi-tag Protein, CF

R&D Systems, part of Bio-Techne | Catalog # AVI2130

Biotinylated
R&D Systems, part of Bio-Techne
Catalog #
Availability
Size / Price
Qty
Loading...
AVI2130-050

Key Product Details

Learn more about Avi-tag Biotinylated Proteins

Source

CHO

Accession #

Structure / Form

Disulfide-linked homodimer, biotinylated via Avi-tag

Conjugate

Biotin

Applications

Bioactivity

Product Specifications

Source

Chinese Hamster Ovary cell line, CHO-derived human Siglec-10 protein
Human Siglec-10
(Met17-Thr546)
Accession # Q96LC7.3
IEGRMD Human IgG1
(Pro100-Lys330)
Avi-tag
N-terminus C-terminus

Purity

>95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.

Endotoxin Level

<0.10 EU per 1 μg of the protein by the LAL method.

N-terminal Sequence Analysis

Met17

Predicted Molecular Mass

87 kDa

SDS-PAGE

95-118 kDa, under reducing conditions

Activity

The biotin to protein ratio is greater than 0.7 as determined by the HABA assay.

Measured by its binding ability in a functional ELISA.
When Recombinant Human CD52 Fc Chimera Protein (Catalog # 9116-CD) is immobilized at 5 μg/mL (100 µL/well), the concentration of Biotinylated Recombinant Human Siglec‑10 Fc Chimera Avi-tag (Catalog # AVI2130) that produces 50% of the optimal binding response is found to be approximately 0.75-4.50 μg/mL.

Scientific Data Images for Recombinant Human Siglec-10 Fc Chimera Avi-tag Protein, CF

Biotinylated Recombinant Human Siglec-10 Fc Chimera Avi-tag Protein Binding Activity.

When Recombinant Human CD52 Fc Chimera Protein (9116-CD) is immobilized at 5 μg/mL (100 µL/well), the concentration of Biotinylated Recombinant Human Siglec‑10 Fc Chimera Avi-tag (Catalog # AVI2130) that produces 50% of the optimal binding response is found to be approximately 0.75-4.50 μg/mL.

Recombinant Human Siglec-10 Fc Chimera Avi-tag Protein SDS-PAGE

2 μg/lane of Recombinant Siglec-10 Fc Chimera Avi-tag (Catalog # AVI2130) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 95-118 kDa and 190-236 kDa, respectively.

Formulation, Preparation and Storage

AVI2130
Formulation Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
Reconstitution Reconstitute at 250 μg/mL in PBS.
Shipping The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.

Background: Siglec-10

Sialic acid-binding Ig-like lectin 10 (Siglec-10), also known as Siglec-like protein 2, is an inhibitory I-type lectin of immune regulators belonging to the immunoglobulin superfamily. Siglecs can be divided into 2 classes: evolutionarily conserved Siglecs and CD33-related Siglecs (1). Siglec-10 falls within the CD33-related Siglecs class and has the closest sequence homology to Siglec-5 and Siglec-3 (2). The extracellular domain (ECD) of human Siglec-10 consists of one V-set domain that plays a role in specific sialoglycans recognition and four Ig-like C2-type domains, a single transmembrane domain and a cytoplasmic tail containing three immunoreceptor tyrosine-based inhibitory motifs (ITIMs) (3). Within the ECD, mature human Siglec-10 shares 63% amino acid sequence identity with mouse and rat Siglec-10. Siglec-10 is expressed on eosinophils, neutrophils, monocytes, and B cells (4, 6) with some splice variants predominating in particular cell types and tissue locations (5, 2, 7). It is upregulated on eosinophils in mouse models of allergic respiratory inflammation (8). Siglec-10 binds sialated proteins and lipids in alpha 2,3 or alpha 2,6 linkage and shows a preference for GT1b gangliosides (2, 9). This binding can be modulated by cis interactions of Siglec-10 with sialated molecules expressed on the same cell (2). When tyrosine phosphorylated, the cytoplasmic ITIMs interact with phosphatases SHP-1 and SHP-2 to propagate inhibitory signals (4, 7). Additionally, Siglec-10 has been shown to interact with soluble CD52 (10). This interaction inhibits the proliferation of activated T cells and the cytotoxic function of autoimmune CD8+ T cells in type 1 diabetes (11). Our Avi-tag Biotinylated Siglec-10 features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

References

  1. Varki, A. and Angata, T. (2006) Glycobiology, 16:1R.
  2. Li, N. et al. (2001) J. Biol. Chem. 276:28106.
  3. Forgione, R. et al. (2020) iScience. 23:101231.
  4. Whitney, G. et al. (2001) Eur. J. Biochem. 268:6083.
  5. Yousef, G.M. et al. (2001) Biochem. Biophys. Res. Commun. 284:900.
  6. Munday, J. et al. (2001) Biochem. J. 355:489.
  7. Kitzig, F. et al. (2002) Biochem. Biophys. Res. Commun. 296:355.
  8. Aizawa, H. et al. (2003) Genomics 82:521.
  9. Rapoport, E. et al. (2003) Bioorg. Med. Chem. Lett. 13:675.
  10. Toh, B.-H. et al. (2013) Cell. Mol. Immunol. 10:379.
  11. Bandala-Sanchez, E. et al. (2013) Nat. Immunol. 14:741.

Long Name

Sialic Acid Binding Ig-like Lectin 10

Alternate Names

Siglec10, SLG2

Entrez Gene IDs

89790 (Human)

Gene Symbol

SIGLEC10

UniProt

Additional Siglec-10 Products

Product Documents for Recombinant Human Siglec-10 Fc Chimera Avi-tag Protein, CF

Certificate of Analysis

To download a Certificate of Analysis, please enter a lot number in the search box below.

Note: Certificate of Analysis not available for kit components.

Product Specific Notices for Recombinant Human Siglec-10 Fc Chimera Avi-tag Protein, CF

For research use only

Loading...
Loading...
Loading...
Loading...